- Home
- DUO vs GTBP Comparison
DUO vs GTBP Comparison
Compare DUO & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DUO
- GTBP
- Stock Information
- Founded
- DUO 2011
- GTBP 1965
- Country
- DUO China
- GTBP United States
- Employees
- DUO N/A
- GTBP N/A
- Industry
- DUO Real Estate
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- DUO Finance
- GTBP Health Care
- Exchange
- DUO Nasdaq
- GTBP Nasdaq
- Market Cap
- DUO 6.1M
- GTBP 5.5M
- IPO Year
- DUO 2019
- GTBP N/A
- Fundamental
- Price
- DUO $3.24
- GTBP $0.79
- Analyst Decision
- DUO
- GTBP Strong Buy
- Analyst Count
- DUO 0
- GTBP 1
- Target Price
- DUO N/A
- GTBP $11.00
- AVG Volume (30 Days)
- DUO 6.2M
- GTBP 449.7K
- Earning Date
- DUO 08-29-2025
- GTBP 11-13-2025
- Dividend Yield
- DUO N/A
- GTBP N/A
- EPS Growth
- DUO N/A
- GTBP N/A
- EPS
- DUO N/A
- GTBP N/A
- Revenue
- DUO $56,189,313.00
- GTBP N/A
- Revenue This Year
- DUO N/A
- GTBP N/A
- Revenue Next Year
- DUO N/A
- GTBP N/A
- P/E Ratio
- DUO N/A
- GTBP N/A
- Revenue Growth
- DUO 48.30
- GTBP N/A
- 52 Week Low
- DUO $1.24
- GTBP $0.63
- 52 Week High
- DUO $74.72
- GTBP $4.10
- Technical
- Relative Strength Index (RSI)
- DUO 56.68
- GTBP 29.57
- Support Level
- DUO $3.00
- GTBP $0.63
- Resistance Level
- DUO $3.59
- GTBP $0.85
- Average True Range (ATR)
- DUO 0.81
- GTBP 0.10
- MACD
- DUO 0.04
- GTBP 0.03
- Stochastic Oscillator
- DUO 45.60
- GTBP 31.22
About DUO Fangdd Network Group Ltd.
Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.